SMARCA4‐deficient thoracic tumors exhibit distinct characteristics from conventional NSCLCs, and PD‐1 inhibitors show promise in treating advanced SMARCA4‐deficient thoracic tumors. The gene discussed is SMARCA4; the disease is neoplasm of thorax.